An investigation of some factors affecting levels of erythrocyte inorganic pyrophosphatase activity

R. A. Fisher(University College London), Harry Harris(University of Cambridge), Henry L. Dorkin(Boston Children's Hospital), Bryan M. Turner(University of Maryland, Baltimore)

Clinica Chimica Acta

May 1, 1975

10.1016/0009-8981(75)90394-0

Cited by 2

Related Papers

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

|Thorax|2011|501

Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis

|New England Journal of Medicine|1993|458

Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs

|Human Molecular Genetics|1993|414

Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial

|Human Gene Therapy|2007|275

Airway area by acoustic reflections measured at the mouth

|Journal of Applied Physiology|1980|250